Patients will be randomized 2:1 ( rivaroxaban : VKA ) using 2 cardioversion strategies : the first approach is early cardioversion with the precardioversion anticoagulation goal of 1 to 5 days using rivaroxaban or usual therapy ( heparin + VKA ) .